Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
46-60 of 4347 results
AstraZeneca’s COPD drug Fasenra fails to meet primary endpoint in phase III trial
By PBR Staff Writer
AstraZeneca’s respiratory drug Fasenra (benralizumab) has failed to meet its primary endpoint in the Galathea phase III trial.
Contract Research & Services > Clinical Trials > News
Merck to invest $125m in Moderna Therapeutics
By PBR Staff Writer
Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.
Contract Research & Services > Clinical Trials > News
Merck signs deal with SFJ on colorectal cancer drug development
Merck has entered into a development agreement with US-based SFJ Pharmaceuticals Group (SFJ) to develop abituzumab in metastatic colorectal cancer.
Contract Research & Services > Clinical Trials > News
Karyopharm’s multiple myeloma drug Selinexor succeeds in phase 2b study
By PBR Staff Writer
Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma.
Contract Research & Services > Clinical Trials > News
Allergan’s ubrogepant migraine drug succeeds in second phase 3 trial
By PBR Staff Writer
Allergan’s migraine drug ubrogepant has succeeded in a phase 3 trial by meeting its co-primary endpoints for a 50mg dose.
Contract Research & Services > Clinical Trials > News
Vertex launches phase 3 trials of VX-445/Tezacaftor/Ivacaftor combo in cystic fibrosis
Vertex Pharmaceuticals has initiated two phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).
Contract Research & Services > Clinical Trials > News
ADC Therapeutics terminates ADCT-502 program targeting HER2 expressing solid tumors
ADC Therapeutics (ADCT) has terminated the phase I clinical trial to assess its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid tumors with HER2 expression.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s lung cancer combo fails in phase III trial
AstraZeneca’s lung cancer combo of Imfinzi (durvalumab) plus tremelimumab has failed to deliver desired results in a phase III trial, called ARCTIC, in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had more than two prior treatments.
Contract Research & Services > Clinical Trials > News
Prothena scraps development of AL amyloidosis drug
By PBR Staff Writer
Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study.
Contract Research & Services > Clinical Trials > News
Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Contract Research & Services > Clinical Trials > News
Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease
Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda significantly decreases risk of disease recurrence in melanoma study
Merck has reported results from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Tagrisso shows sustained PFS in phase 3 lung cancer trial
By PBR Staff Writer
AstraZeneca said that Tagrisso (osimertinib) in a first line setting has shown significant progression-free survival (PFS) benefit that was preserved through subsequent lines of therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Personalized tumor vaccine yields promising results in pilot trial
A new type of cancer vaccine has shown promise in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.
Contract Research & Services > Clinical Trials > News
Futility forces Pfizer to stop phase 3 trial of Inlyta for recurrent renal cell carcinoma
By PBR Staff Writer
The independent data monitoring committee (DMC) has recommended the termination of a phase 3 clinical trial assessing Pfizer's Inlyta (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy due to futility.
Contract Research & Services > Clinical Trials > News
46-60 of 4347 results